Iqvia Holdings Inc (NYSE:IQV) Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of Iqvia stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.80, for a total transaction of $569,462,784.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
IQV opened at $140.98 on Friday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 1.10 and a current ratio of 1.10. Iqvia Holdings Inc has a fifty-two week low of $91.57 and a fifty-two week high of $144.77. The firm has a market cap of $27.66 billion, a P/E ratio of 27.54, a PEG ratio of 1.70 and a beta of 0.85.
Iqvia (NYSE:IQV) last released its earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.03. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The company had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter in the previous year, the company earned $1.40 EPS. Iqvia’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, equities analysts expect that Iqvia Holdings Inc will post 5.87 earnings per share for the current year.
Several brokerages have recently weighed in on IQV. Argus lifted their price target on shares of Iqvia from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Wells Fargo & Co lifted their price target on shares of Iqvia from $140.00 to $160.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 19th. Barclays reiterated a “buy” rating and set a $155.00 price target on shares of Iqvia in a research note on Friday, February 15th. UBS Group set a $170.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research note on Friday, February 15th. Finally, Piper Jaffray Companies lifted their price target on shares of Iqvia to $148.00 and gave the stock a “neutral” rating in a research note on Friday, February 15th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $146.13.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CENTRAL TRUST Co lifted its stake in Iqvia by 1,150.0% in the 4th quarter. CENTRAL TRUST Co now owns 375 shares of the medical research company’s stock worth $44,000 after purchasing an additional 345 shares in the last quarter. Berman Capital Advisors LLC purchased a new stake in Iqvia in the 4th quarter worth $46,000. ERTS Wealth Advisors LLC purchased a new stake in Iqvia in the 4th quarter worth $46,000. Kaizen Advisory LLC lifted its stake in Iqvia by 33.1% in the 4th quarter. Kaizen Advisory LLC now owns 450 shares of the medical research company’s stock worth $52,000 after purchasing an additional 112 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in Iqvia in the 4th quarter worth $59,000. Institutional investors own 89.58% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Iqvia Holdings Inc (IQV) Director Group Holdings (Sbs) Advis Tpg Sells 4,044,480 Shares” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://transcriptdaily.com/2019/03/15/iqvia-holdings-inc-iqv-director-group-holdings-sbs-advis-tpg-sells-4044480-shares.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: What Are Cryptocurrencies?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.